Secop Group and B Medical Systems announce a joint development agreement

Secop GmbH, a globally leading provider of advanced cooling solutions for mobile, battery-powered applications, commercial and medical cold chains, and B Medical Systems, a worldwide leader in cold chain solutions for vaccines and a leading manufacturer of medical cold chain solutions, have announced a joint development agreement to create solutions for a new generation of medical transport boxes that enable the safe storage and transport of vaccines, bioprobes, and other temperature-sensitive samples at extremely low temperatures, even in locations with tropical environmental conditions.

The COVID-19 pandemic, the increasing adoption of mRNA technology, the development of several extremely temperature-sensitive vaccines, the growing importance of cell and gene therapy (CGT), and more have led to a steadily rising demand for reliable medical cold chain solutions at ultra-low temperatures. In their collaboration, SECOP and B Medical Systems aim to offer a reliable and effective active medical cold chain solution through an active transport unit equipped with a cascade compressor system specifically designed to achieve ultralow temperatures even under tropical environmental conditions. As part of this agreement, SECOP and B Medical Systems will conduct a series of development and testing activities, leveraging SECOP's decades of experience in efficient mobile cooling compressors and B Medical Systems' expertise in developing innovative and reliable solutions for medical transport boxes.

"Secop's engineering team has conducted intensive development and testing activities to prototype and optimize an innovative cooling unit powered by a cascade of battery-operated compressors, specifically optimized for medical applications, capable of reaching, maintaining, and guaranteeing extremely low temperatures down to -86°C," says Jan Ehlers, CEO of Secop GmbH. "This is the temperature range required for the new generation of mRNA-based COVID-19 vaccines, even at an ambient temperature of 43°C. This development agreement with B Medical Systems is a significant step forward for the SECOP Group. Both companies can combine their capabilities and technologies to support the successful development of a truly groundbreaking product that promotes sustainable cold chain development and helps improve the storage and delivery of vaccines worldwide."

"The ability to reliably transport vaccines and temperature-sensitive samples at extremely low temperatures is becoming increasingly important," says Luc Provost, CEO of B Medical Systems. "The Joint Development Agreement (JDA) is a significant step in our journey to provide this next generation of ultra-low temperature cold chain devices. By combining Secop's expertise in compressor technology with B Medical Systems' experience in developing innovative medical cold chain solutions, I am confident that we will soon be able to offer the market a convenient and reliable solution for the safe storage and transport of small quantities of vaccines, medicines, and samples at ultralow temperatures."

The research and development teams of Secop and B Medical Systems are currently working on joint development activities under the agreement, and both companies aim to complete the development and testing phases soon to bring this new ultralow temperature cold chain solution to market.